{"transactions":[{"id":4636433,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-10-06T21:54:13.000Z","date":"2026-10-02","kind":"sale","planned":true,"acquired":false,"shares":797,"price":21.17,"value":16872.49,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer."}],"balance_after":23087,"source":{"system":"sec-edgar","filing":"0001919246-26-000131","document":"wk-form4_1791323650.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1919246/000191924626000131/wk-form4_1791323650.xml","form_type":"4"}},{"id":713461,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-07T21:03:21.000Z","date":"2026-07-02","kind":"sale","planned":true,"acquired":false,"shares":85,"price":27.2733,"value":2318.2305,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $27.20 to $27.63. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":23884,"source":{"system":"sec-edgar","filing":"0001919246-26-000100","document":"wk-form4_1783458198.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000191924626000100/wk-form4_1783458198.xml","form_type":"4"}},{"id":713460,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-07T21:03:21.000Z","date":"2026-07-02","kind":"sale","planned":true,"acquired":false,"shares":712,"price":25.9954,"value":18508.7248,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $25.58 to $26.53. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":23969,"source":{"system":"sec-edgar","filing":"0001919246-26-000100","document":"wk-form4_1783458198.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000191924626000100/wk-form4_1783458198.xml","form_type":"4"}},{"id":814318,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-06T21:01:00.000Z","date":"2026-04-02","kind":"sale","planned":true,"acquired":false,"shares":377,"price":21.3614,"value":8053.2478,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $21.31 to $22.03. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":24681,"source":{"system":"sec-edgar","filing":"0001919246-26-000052","document":"wk-form4_1775509257.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000191924626000052/wk-form4_1775509257.xml","form_type":"4"}},{"id":814317,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-06T21:01:00.000Z","date":"2026-04-02","kind":"sale","planned":true,"acquired":false,"shares":420,"price":20.5151,"value":8616.342,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $20.30 to $20.78. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":25058,"source":{"system":"sec-edgar","filing":"0001919246-26-000052","document":"wk-form4_1775509257.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000191924626000052/wk-form4_1775509257.xml","form_type":"4"}},{"id":822636,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-01T21:43:41.000Z","date":"2025-07-02","kind":"grant","planned":false,"acquired":true,"shares":25478,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares of common stock, par value $0.0001 per share (\"Common Stock\") of Pelthos Therapeutics Inc. (the \"Issuer\"), issuable upon settlement of restricted stock units of the Issuer (\"RSUs\") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the \"2023 Plan\"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4 filed by the reporting person (the \"Original Form 4\").  This Form 4 amendment (this \"Amendment\") is being filed to amend the Original Form 4 in order to report the grant of such RSUs in Table I."},{"field":"shares","element":"transactionShares","label":"F2","text":"The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest as follows: the initial one-third of shares vested on July 2, 2025, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two years, so long as the reporting person remains in the service of the Issuer on each such anniversary."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest as follows: the initial one-third of shares vested on July 2, 2025, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two years, so long as the reporting person remains in the service of the Issuer on each such anniversary."}],"balance_after":25478,"source":{"system":"sec-edgar","filing":"0001919246-26-000043","document":"wk-form4a_1775079819.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000191924626000043/wk-form4a_1775079819.xml","form_type":"4/A","original_submission_date":"2025-07-07"}},{"id":865752,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-03-03T21:13:51.000Z","date":"2026-02-27","kind":"grant","planned":false,"acquired":true,"shares":328424,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter."}],"balance_after":328424,"derivative":{"exercise_price":13.97,"expiration_date":"2036-02-27","underlying":"Common Stock","underlying_shares":328424},"source":{"system":"sec-edgar","filing":"0001600620-26-000021","document":"wk-form4_1772572423.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000160062026000021/wk-form4_1772572423.xml","form_type":"4"}},{"id":865751,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-03T21:13:51.000Z","date":"2026-03-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":100890,"price":14.21,"value":1433646.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock units."}],"balance_after":1840379,"source":{"system":"sec-edgar","filing":"0001600620-26-000021","document":"wk-form4_1772572423.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000160062026000021/wk-form4_1772572423.xml","form_type":"4"}},{"id":865750,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-03T21:13:51.000Z","date":"2026-02-27","kind":"grant","planned":false,"acquired":true,"shares":196403,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each performance right represents a contingent right to receive one common share of the Issuer. The performance rights vest in four tranches upon the Issuer's common shares achieving four\nprogressively higher target prices, with respective one year retention periods per tranche achievement."}],"balance_after":1941269,"source":{"system":"sec-edgar","filing":"0001600620-26-000021","document":"wk-form4_1772572423.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000160062026000021/wk-form4_1772572423.xml","form_type":"4"}},{"id":887658,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-23T21:07:03.000Z","date":"2026-02-20","kind":"tax_withholding","planned":false,"acquired":false,"shares":100171,"price":14.4,"value":1442462.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock units."}],"balance_after":1744866,"source":{"system":"sec-edgar","filing":"0001363683-26-000002","document":"wk-form4_1771880820.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000136368326000002/wk-form4_1771880820.xml","form_type":"4"}},{"id":950457,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-05T21:10:03.000Z","date":"2026-01-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":113169,"price":15.95,"value":1805045.55,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld to satisfy tax withholding obligations upon the vesting of performance awards."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes common shares acquired by the reporting person pursuant to the Issuer's 2021 Employee Share Purchase Plan as follows: 2,257 common shares were acquired on May 30, 2025 and 1,620\ncommon shares were acquired on November 28, 2025."}],"balance_after":1845037,"source":{"system":"sec-edgar","filing":"0001600620-26-000002","document":"wk-form4_1767647395.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000160062026000002/wk-form4_1767647395.xml","form_type":"4"}},{"id":950456,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-05T21:10:03.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":165384,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares earned upon certification of performance for a performance award payable solely in common shares of the Issuer that vest in two (2) equal annual installments on December 31, 2025 and December 31, 2026."}],"balance_after":1954329,"source":{"system":"sec-edgar","filing":"0001600620-26-000002","document":"wk-form4_1767647395.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000160062026000002/wk-form4_1767647395.xml","form_type":"4"}},{"id":1091174,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-07-08T01:46:35.000Z","date":"2025-07-02","kind":"grant","planned":false,"acquired":true,"shares":77640,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On July 2, 2025, the Reporting Person was granted stock options to purchase 77,640 shares of common stock at an exercise price of $13.50 per share, with the initial one third (1/3) of such shares vesting on July 2, 2025, and in equal installments on a quarterly basis thereafter over a period of two (2) years."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On July 2, 2025, the Reporting Person was granted stock options to purchase 77,640 shares of common stock at an exercise price of $13.50 per share, with the initial one third (1/3) of such shares vesting on July 2, 2025, and in equal installments on a quarterly basis thereafter over a period of two (2) years."}],"balance_after":77640,"derivative":{"exercise_price":13.5,"exercise_date":"2026-07-02","expiration_date":"2035-07-02","underlying":"Common Stock","underlying_shares":77640},"source":{"system":"sec-edgar","filing":"0001753926-25-001108","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000175392625001108/ownership.xml","form_type":"4"}},{"id":1091173,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-07-08T01:46:35.000Z","date":"2025-07-02","kind":"grant","planned":false,"acquired":true,"shares":25478,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 2, 2025, the Reporting Person was granted restricted stock units to purchase 25,478 shares of common stock at an exercise price of $13.50 per share, with the initial one third (1/3) of such shares vesting on July 2, 2025, and in equal installments on a quarterly basis thereafter over a period of two (2) years."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 2, 2025, the Reporting Person was granted restricted stock units to purchase 25,478 shares of common stock at an exercise price of $13.50 per share, with the initial one third (1/3) of such shares vesting on July 2, 2025, and in equal installments on a quarterly basis thereafter over a period of two (2) years."}],"balance_after":25478,"derivative":{"exercise_price":13.5,"exercise_date":"2026-07-02","expiration_date":"2035-07-02","underlying":"Common Stock","underlying_shares":25478},"source":{"system":"sec-edgar","filing":"0001753926-25-001108","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000175392625001108/ownership.xml","form_type":"4"}},{"id":1227103,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-03-05T02:02:08.000Z","date":"2025-02-28","kind":"grant","planned":false,"acquired":true,"shares":443973,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter."}],"balance_after":443973,"derivative":{"exercise_price":7.55,"expiration_date":"2035-02-28","underlying":"Common Stock","underlying_shares":443973},"source":{"system":"sec-edgar","filing":"0001600620-25-000024","document":"wk-form4_1741140121.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000160062025000024/wk-form4_1741140121.xml","form_type":"4"}},{"id":1227102,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-03-05T02:02:08.000Z","date":"2025-03-04","kind":"sale","planned":false,"acquired":false,"shares":164947,"price":7.92,"value":1306380.24,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F6","text":"Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of RSUs related to the March 2, 2022 and March 2, 2023 grants."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.76 to $8.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1788945,"source":{"system":"sec-edgar","filing":"0001600620-25-000024","document":"wk-form4_1741140121.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000160062025000024/wk-form4_1741140121.xml","form_type":"4"}},{"id":1227101,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-03-05T02:02:08.000Z","date":"2025-03-03","kind":"sale","planned":false,"acquired":false,"shares":195593,"price":8,"value":1564744.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) related to the February 20, 2024 grant and March 2, 2023 performance award."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.79 to $8.13, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1953892,"source":{"system":"sec-edgar","filing":"0001600620-25-000024","document":"wk-form4_1741140121.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000160062025000024/wk-form4_1741140121.xml","form_type":"4"}},{"id":1227100,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-03-05T02:02:08.000Z","date":"2025-03-03","kind":"grant","planned":false,"acquired":true,"shares":333705,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents grant of performance award payable solely in common shares of the Issuer that vest in two (2) equal annual installments on December 31, 2024 and December 31, 2025."}],"balance_after":2149485,"source":{"system":"sec-edgar","filing":"0001600620-25-000024","document":"wk-form4_1741140121.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000160062025000024/wk-form4_1741140121.xml","form_type":"4"}},{"id":1227099,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-03-05T02:02:08.000Z","date":"2025-02-28","kind":"grant","planned":false,"acquired":true,"shares":290728,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each performance right represents a contingent right to receive one common share of the Issuer. The performance rights vest in four tranches upon the Issuer's common shares achieving four\nprogressively higher target prices, with respective one year retention periods per tranche achievement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes common shares acquired by the reporting person pursuant to the Issuer's 2021 Employee Share Purchase Plan as follows: 2,500 common shares were acquired on May 31, 2024 and 438 common shares were acquired on November 29, 2024."}],"balance_after":1815780,"source":{"system":"sec-edgar","filing":"0001600620-25-000024","document":"wk-form4_1741140121.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000160062025000024/wk-form4_1741140121.xml","form_type":"4"}},{"id":1588801,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-03-07T21:46:19.000Z","date":"2024-03-06","kind":"sale","planned":false,"acquired":false,"shares":126981,"price":5.6,"value":711093.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of Restricted Stock Units related to the March 2, 2022 and March 2, 2023 grants."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.475 to $5.755, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1522114,"source":{"system":"sec-edgar","filing":"0001600620-24-000038","document":"wk-form4_1709847968.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000160062024000038/wk-form4_1709847968.xml","form_type":"4"}},{"id":1624944,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-02-22T21:25:08.000Z","date":"2024-02-20","kind":"grant","planned":false,"acquired":true,"shares":661538,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of Restricted Stock Units (RSUs) payable solely in common stock of the Issuer that vest in three (3) equal annual installments on the first, second and third anniversary of the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes shares of common stock acquired by the reporting person pursuant to the Issuer's 2021 Employee Share Purchase Plan as follows: 2,386 shares of common stock were acquired on May 31, 2023 and 2,500 shares of common stock were acquired on November 30, 2023."}],"balance_after":1649095,"source":{"system":"sec-edgar","filing":"0001600620-24-000017","document":"wk-form4_1708637079.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000160062024000017/wk-form4_1708637079.xml","form_type":"4"}},{"id":1624941,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-02-22T21:15:26.000Z","date":"2023-03-02","kind":"sale","planned":false,"acquired":false,"shares":33047,"price":8.78,"value":290152.66,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of RSUs."}],"balance_after":982671,"source":{"system":"sec-edgar","filing":"0001600620-24-000013","document":"wk-form4a_1708636492.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000160062024000013/wk-form4a_1708636492.xml","form_type":"4/A","original_submission_date":"2023-03-06"}},{"id":1968538,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-03-06T21:27:56.000Z","date":"2023-03-02","kind":"sale","acquired":false,"shares":32750,"price":8.94,"value":292785.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of RSUs."}],"balance_after":982968,"source":{"system":"sec-edgar","filing":"0001628280-23-006526","document":"wf-form4_167813805672591.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000162828023006526/wf-form4_167813805672591.xml","form_type":"4"}},{"id":1968537,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-03-06T21:27:56.000Z","date":"2023-03-02","kind":"grant","acquired":true,"shares":667407,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of Restricted Stock Units (RSUs) payable solely in common stock of the Issuer that vest in three (3) equal annual installments on the first, second and third anniversary of the grant date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of the Issuer's common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes shares of common stock acquired by the reporting person pursuant to the Issuer's 2021 Employee Share Purchase Plan as follows: 1,221 shares of common stock were acquired on May 31, 2022 and 1,883 shares of common stock were acquired on November 30, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The reporting person has reported prior awards of restricted stock units in Table II of Form 4. The total reported in Column 5 includes the 667,407 newly awarded RSUs, 312,240 RSUs previously reported in Table II, which vests in three (3) equal annual installments beginning March 2, 2022 (Prior RSUs), and 32,967 shares of common stock. On March 2, 2023, 104,080 of Prior RSUs vested and 208,160 of Prior RSUs remained unvested."}],"balance_after":1015718,"source":{"system":"sec-edgar","filing":"0001628280-23-006526","document":"wf-form4_167813805672591.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000162828023006526/wf-form4_167813805672591.xml","form_type":"4"}},{"id":2255751,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-05-26T17:22:14.000Z","date":"2022-05-24","kind":"disposition_to_issuer","acquired":false,"shares":48542,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."}],"balance_after":0,"derivative":{"exercise_price":4.42,"underlying":"Common Stock","underlying_shares":48542},"source":{"system":"sec-edgar","filing":"0000899243-22-019780","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000089924322019780/doc4.xml","form_type":"4"}},{"id":2255750,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-05-26T17:22:14.000Z","date":"2022-05-24","kind":"disposition_to_issuer","acquired":false,"shares":58246,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."}],"balance_after":0,"derivative":{"exercise_price":2.73,"underlying":"Common Stock","underlying_shares":58246},"source":{"system":"sec-edgar","filing":"0000899243-22-019780","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000089924322019780/doc4.xml","form_type":"4"}},{"id":2255749,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-05-26T17:22:14.000Z","date":"2022-05-24","kind":"disposition_to_issuer","acquired":false,"shares":46729,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."}],"balance_after":0,"derivative":{"exercise_price":2.92,"underlying":"Common Stock","underlying_shares":46729},"source":{"system":"sec-edgar","filing":"0000899243-22-019780","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000089924322019780/doc4.xml","form_type":"4"}},{"id":2255748,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-05-26T17:22:14.000Z","date":"2022-05-24","kind":"disposition_to_issuer","acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."}],"balance_after":0,"derivative":{"exercise_price":3.11,"underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-22-019780","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000089924322019780/doc4.xml","form_type":"4"}},{"id":2255747,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-26T17:22:14.000Z","date":"2022-05-24","kind":"disposition_to_issuer","acquired":false,"shares":49425,"price":5.6,"value":276780.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Each Company restricted stock unit (\"Company RSU\") means any restricted stock unit granted under the Company Equity Plan. At the Effective Time, each Company RSU that was outstanding immediately prior to the Effective Time was cancelled at the Effective Time and converted into the right to receive a cash payment equal to the product of (i) the number of Shares issuable in settlement of the Company RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration."},{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of April 12, 2022, by and among the Issuer, Antares Pharma, Inc., a Delaware corporation (the \"Company\"),  Halozyme Therapeutics, Inc., a Delaware corporation (\"Parent\"), and Atlas Merger Sub, Inc., a Delaware corporation (\"Purchaser\") and a wholly owned subsidiary of Parent, to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.01 par value per share (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of May 24, 2022 (the \"Effective Time\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) At the Effective Time, each Share outstanding immediately prior to the Effective Time (other than Excluded Shares) was converted into the right to receive $5.60 in cash, without interest (the \"Merger Consideration\") and subject to any withholding of taxes required by applicable legal requirements, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-019780","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000089924322019780/doc4.xml","form_type":"4"}},{"id":2255746,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-26T17:22:14.000Z","date":"2022-05-24","kind":"disposition_to_issuer","acquired":false,"shares":30220,"price":5.6,"value":169232.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of April 12, 2022, by and among the Issuer, Antares Pharma, Inc., a Delaware corporation (the \"Company\"),  Halozyme Therapeutics, Inc., a Delaware corporation (\"Parent\"), and Atlas Merger Sub, Inc., a Delaware corporation (\"Purchaser\") and a wholly owned subsidiary of Parent, to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.01 par value per share (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of May 24, 2022 (the \"Effective Time\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) At the Effective Time, each Share outstanding immediately prior to the Effective Time (other than Excluded Shares) was converted into the right to receive $5.60 in cash, without interest (the \"Merger Consideration\") and subject to any withholding of taxes required by applicable legal requirements, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-019780","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000089924322019780/doc4.xml","form_type":"4"}},{"id":2321924,"issuer":{"id":128876,"kind":"organization","name":"BIODELIVERY SCIENCES INTERNATIONAL INC","symbol":"BDSI"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2022-03-22T17:12:46.000Z","date":"2022-03-22","kind":"disposition_to_issuer","acquired":false,"shares":114347,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."}],"balance_after":0,"derivative":{"exercise_price":3.66,"underlying":"Common Stock","underlying_shares":114347},"source":{"system":"sec-edgar","filing":"0001103021-22-000067","document":"wf-form4_164798354676336.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1103021/000110302122000067/wf-form4_164798354676336.xml","form_type":"4"}},{"id":2321923,"issuer":{"id":128876,"kind":"organization","name":"BIODELIVERY SCIENCES INTERNATIONAL INC","symbol":"BDSI"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2022-03-22T17:12:46.000Z","date":"2022-03-22","kind":"disposition_to_issuer","acquired":false,"shares":64164,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."}],"balance_after":0,"derivative":{"exercise_price":2.93,"underlying":"Common Stock","underlying_shares":64164},"source":{"system":"sec-edgar","filing":"0001103021-22-000067","document":"wf-form4_164798354676336.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1103021/000110302122000067/wf-form4_164798354676336.xml","form_type":"4"}},{"id":2321922,"issuer":{"id":128876,"kind":"organization","name":"BIODELIVERY SCIENCES INTERNATIONAL INC","symbol":"BDSI"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-03-22T17:12:46.000Z","date":"2022-03-22","kind":"disposition_to_issuer","acquired":false,"shares":27746,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive one Share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each Issuer RSUs that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the Merger Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each Issuer RSUs that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each Issuer RSUs that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the Merger Consideration."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":27746},"source":{"system":"sec-edgar","filing":"0001103021-22-000067","document":"wf-form4_164798354676336.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1103021/000110302122000067/wf-form4_164798354676336.xml","form_type":"4"}},{"id":2321921,"issuer":{"id":128876,"kind":"organization","name":"BIODELIVERY SCIENCES INTERNATIONAL INC","symbol":"BDSI"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-03-22T17:12:46.000Z","date":"2022-03-22","kind":"other","acquired":false,"shares":105034,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of February 14, 2022, by and among the Issuer, Collegium Pharmaceutical, Inc., (\"Parent\"), and Bristol Acquisition Company Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a tender offer for shares of common stock of Issuer, $0.001 par value per share (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of March 22, 2022 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $5.60 in cash (the \"Merger Consideration\") without interest and subject to applicable withholding taxes."},{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of February 14, 2022, by and among the Issuer, Collegium Pharmaceutical, Inc., (\"Parent\"), and Bristol Acquisition Company Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a tender offer for shares of common stock of Issuer, $0.001 par value per share (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of March 22, 2022 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $5.60 in cash (the \"Merger Consideration\") without interest and subject to applicable withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of February 14, 2022, by and among the Issuer, Collegium Pharmaceutical, Inc., (\"Parent\"), and Bristol Acquisition Company Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a tender offer for shares of common stock of Issuer, $0.001 par value per share (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of March 22, 2022 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $5.60 in cash (the \"Merger Consideration\") without interest and subject to applicable withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001103021-22-000067","document":"wf-form4_164798354676336.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1103021/000110302122000067/wf-form4_164798354676336.xml","form_type":"4"}},{"id":2349821,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-03-04T21:11:27.000Z","date":"2022-03-02","kind":"grant","acquired":true,"shares":534188,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter."}],"balance_after":534188,"derivative":{"exercise_price":12.01,"expiration_date":"2032-03-02","underlying":"Common Stock","underlying_shares":534188},"source":{"system":"sec-edgar","filing":"0001628280-22-005123","document":"wf-form4_164642827067393.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000162828022005123/wf-form4_164642827067393.xml","form_type":"4"}},{"id":2349820,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Unit","published_at":"2022-03-04T21:11:27.000Z","date":"2022-03-02","kind":"grant","acquired":true,"shares":312240,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date."}],"balance_after":312240,"derivative":{"underlying":"Common Shares","underlying_shares":312240},"source":{"system":"sec-edgar","filing":"0001628280-22-005123","document":"wf-form4_164642827067393.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000162828022005123/wf-form4_164642827067393.xml","form_type":"4"}},{"id":2349819,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-03-04T21:11:27.000Z","date":"2022-03-02","kind":"sale","acquired":false,"shares":9068,"price":12.01,"value":108906.68,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of shares sold to cover tax withholding obligations in connection with the vesting of Performance Awards."}],"balance_after":32967,"source":{"system":"sec-edgar","filing":"0001628280-22-005123","document":"wf-form4_164642827067393.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000162828022005123/wf-form4_164642827067393.xml","form_type":"4"}},{"id":2349818,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-03-04T21:11:27.000Z","date":"2022-03-02","kind":"grant","acquired":true,"shares":28300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On March 18, 2021, the Reporting Person was granted stock based performance awards (\"Performance Awards\") which vests when specific performance metrics are met based on the results for the year ended December 31, 2021. It was determined that as of March 2, 2022, the Reporting Person partially met the performance criteria and received shares of common stock for no consideration."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 282 shares acquired by the Reporting Person under the Issuer's 2021 Employee Share Purchase Plan on December 1, 2021."}],"balance_after":42035,"source":{"system":"sec-edgar","filing":"0001628280-22-005123","document":"wf-form4_164642827067393.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000162828022005123/wf-form4_164642827067393.xml","form_type":"4"}},{"id":2421343,"issuer":{"id":128876,"kind":"organization","name":"BIODELIVERY SCIENCES INTERNATIONAL INC","symbol":"BDSI"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-01-31T18:02:12.000Z","date":"2022-01-27","kind":"exercise","acquired":false,"shares":10246,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options were issued to the Reporting Person on January 27, 2022, as compensation for service on the Issuer's board of directors, pursuant to a grant under the Plan. The award is subject to time-based vesting and vests in equal portions on: (i) January 27, 2022; and (ii) January 27, 2023."}],"balance_after":10246,"derivative":{"exercise_price":0,"expiration_date":"2023-01-27","underlying":"Common Stock","underlying_shares":10246},"source":{"system":"sec-edgar","filing":"0001103021-22-000021","document":"wf-form4_164367011540849.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1103021/000110302122000021/wf-form4_164367011540849.xml","form_type":"4"}},{"id":2421342,"issuer":{"id":128876,"kind":"organization","name":"BIODELIVERY SCIENCES INTERNATIONAL INC","symbol":"BDSI"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-01-31T18:02:12.000Z","date":"2022-01-27","kind":"grant","acquired":true,"shares":20492,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The restricted stock units (\"RSUs\") were issued to the Reporting Person as compensation for service on the Company's board of directors, pursuant to a grant under the Issuer's 2019 Stock Option Incentive Plan (\"the Plan\"). The RSUs vest in equal portions on: (i) January 27, 2022; and (ii) January 27, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The restricted stock units (\"RSUs\") were issued to the Reporting Person as compensation for service on the Company's board of directors, pursuant to a grant under the Issuer's 2019 Stock Option Incentive Plan (\"the Plan\"). The RSUs vest in equal portions on: (i) January 27, 2022; and (ii) January 27, 2023."}],"balance_after":20492,"derivative":{"exercise_price":0,"expiration_date":"2023-01-27","underlying":"Common Stock","underlying_shares":20492},"source":{"system":"sec-edgar","filing":"0001103021-22-000021","document":"wf-form4_164367011540849.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1103021/000110302122000021/wf-form4_164367011540849.xml","form_type":"4"}},{"id":2421341,"issuer":{"id":128876,"kind":"organization","name":"BIODELIVERY SCIENCES INTERNATIONAL INC","symbol":"BDSI"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2022-01-31T18:02:12.000Z","date":"2022-01-27","kind":"grant","acquired":true,"shares":114347,"price":3.66,"value":418510.02,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on January 27, 2022."},{"field":"kind","element":"transactionCoding","label":"F3","text":"The stock options were issued to the Reporting Person on January 27, 2022, as compensation for service on the Issuer's board of directors, pursuant to a grant under the Plan. The award is subject to time-based vesting and vests in equal portions on: (i) January 27, 2022; and (ii) January 27, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options were issued to the Reporting Person on January 27, 2022, as compensation for service on the Issuer's board of directors, pursuant to a grant under the Plan. The award is subject to time-based vesting and vests in equal portions on: (i) January 27, 2022; and (ii) January 27, 2023."}],"balance_after":114347,"derivative":{"exercise_price":3.66,"expiration_date":"2032-01-26","underlying":"Common Stock","underlying_shares":114347},"source":{"system":"sec-edgar","filing":"0001103021-22-000021","document":"wf-form4_164367011540849.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1103021/000110302122000021/wf-form4_164367011540849.xml","form_type":"4"}},{"id":2421340,"issuer":{"id":128876,"kind":"organization","name":"BIODELIVERY SCIENCES INTERNATIONAL INC","symbol":"BDSI"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-31T18:02:12.000Z","date":"2022-01-27","kind":"exercise","acquired":true,"shares":10246,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units (\"RSUs\") were issued to the Reporting Person as compensation for service on the Company's board of directors, pursuant to a grant under the Issuer's 2019 Stock Option Incentive Plan (\"the Plan\"). The RSUs vest in equal portions on: (i) January 27, 2022; and (ii) January 27, 2023."}],"balance_after":105034,"source":{"system":"sec-edgar","filing":"0001103021-22-000021","document":"wf-form4_164367011540849.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1103021/000110302122000021/wf-form4_164367011540849.xml","form_type":"4"}},{"id":2608816,"issuer":{"id":128876,"kind":"organization","name":"BIODELIVERY SCIENCES INTERNATIONAL INC","symbol":"BDSI"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2021-08-10T18:17:36.000Z","date":"2021-08-06","kind":"exercise","acquired":false,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (\"RSUs\") granted to the Reporting Person on August 1, 2018 under the Issuer's 2011 Equity Incentive Plan, as amended. The remaining RSUs under this grant will vest as follows: (i) 17,500 RSUs vest in the first open window following the Company's 2022 Annual Meeting of Stockholders."}],"balance_after":17500,"derivative":{"exercise_price":0,"expiration_date":"2022-08-01","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001103021-21-000070","document":"wf-form4_162863384146877.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1103021/000110302121000070/wf-form4_162863384146877.xml","form_type":"4"}},{"id":2608815,"issuer":{"id":128876,"kind":"organization","name":"BIODELIVERY SCIENCES INTERNATIONAL INC","symbol":"BDSI"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-10T18:17:36.000Z","date":"2021-08-06","kind":"exercise","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":94788,"source":{"system":"sec-edgar","filing":"0001103021-21-000070","document":"wf-form4_162863384146877.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1103021/000110302121000070/wf-form4_162863384146877.xml","form_type":"4"}},{"id":2670748,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-14T18:22:12.000Z","date":"2021-06-10","kind":"grant","acquired":true,"shares":48542,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents grant of options to purchase shares of common stock, par value $0.01 per share, issued under the Antares Pharma, Inc. Equity Compensation Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vest and become exercisable one year from the grant date."}],"balance_after":48542,"derivative":{"exercise_price":4.42,"expiration_date":"2031-06-10","underlying":"Common Stock","underlying_shares":48542},"source":{"system":"sec-edgar","filing":"0001209191-21-040329","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919121040329/doc4.xml","form_type":"4"}},{"id":2670747,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-14T18:22:12.000Z","date":"2021-06-10","kind":"grant","acquired":true,"shares":25452,"price":4.42,"value":112497.84,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of restricted stock units made under the Antares Pharma, Inc. Equity Compensation Plan. The shares vest one year from the grant date."}],"balance_after":79645,"source":{"system":"sec-edgar","filing":"0001209191-21-040329","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919121040329/doc4.xml","form_type":"4"}},{"id":2715965,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-05-12T20:32:25.000Z","date":"2021-05-11","kind":"purchase","acquired":true,"shares":2992,"price":11.11,"value":33241.12,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $10.91 to $11.275, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":13453,"source":{"system":"sec-edgar","filing":"0001628280-21-010022","document":"wf-form4_162085152431857.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000162828021010022/wf-form4_162085152431857.xml","form_type":"4"}},{"id":2715964,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-05-12T20:32:25.000Z","date":"2021-05-11","kind":"purchase","acquired":true,"shares":2133,"price":10.15,"value":21649.95,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price in column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $9.74 to $10.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":10461,"source":{"system":"sec-edgar","filing":"0001628280-21-010022","document":"wf-form4_162085152431857.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000162828021010022/wf-form4_162085152431857.xml","form_type":"4"}},{"id":3062268,"issuer":{"id":128876,"kind":"organization","name":"BIODELIVERY SCIENCES INTERNATIONAL INC","symbol":"BDSI"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-08-11T17:03:54.000Z","date":"2020-08-07","kind":"exercise","acquired":false,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (\"RSUs\") granted to the Reporting Person on August 1, 2018 under the Issuer's 2011 Equity Incentive Plan, as amended. The remaining RSUs under this grant will vest as follows: (i) 35,000 RSUs vest in the first open window following the Company's 2021 Annual Meeting of Stockholders and (ii) 17,500 RSUs vest in the first open window following the Company's 2022 Annual Meeting of Stockholders."}],"balance_after":52500,"derivative":{"exercise_price":0,"expiration_date":"2022-08-01","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001103021-20-000132","document":"wf-form4_159717982037683.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1103021/000110302120000132/wf-form4_159717982037683.xml","form_type":"4"}},{"id":3062267,"issuer":{"id":128876,"kind":"organization","name":"BIODELIVERY SCIENCES INTERNATIONAL INC","symbol":"BDSI"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-08-11T17:03:54.000Z","date":"2020-08-07","kind":"exercise","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (\"RSUs\") granted to the Reporting Person on August 1, 2018 under the Issuer's 2011 Equity Incentive Plan, as amended. The remaining RSUs under this grant will vest as follows: (i) 35,000 RSUs vest in the first open window following the Company's 2021 Annual Meeting of Stockholders and (ii) 17,500 RSUs vest in the first open window following the Company's 2022 Annual Meeting of Stockholders."}],"balance_after":59788,"source":{"system":"sec-edgar","filing":"0001103021-20-000132","document":"wf-form4_159717982037683.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1103021/000110302120000132/wf-form4_159717982037683.xml","form_type":"4"}},{"id":3110942,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-15T19:02:57.000Z","date":"2020-06-11","kind":"grant","acquired":true,"shares":58246,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents grant of options to purchase shares of common stock, par value $0.01 per share, issued under the Antares Pharma, Inc. Equity Compensation Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vest and become exercisable one year from the grant date."}],"balance_after":58246,"derivative":{"exercise_price":2.73,"expiration_date":"2030-06-11","underlying":"Common Stock","underlying_shares":58246},"source":{"system":"sec-edgar","filing":"0001209191-20-036771","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919120036771/doc4.xml","form_type":"4"}},{"id":3110941,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-15T19:02:57.000Z","date":"2020-06-11","kind":"grant","acquired":true,"shares":30220,"price":2.73,"value":82500.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of restricted stock units made under the Antares Pharma, Inc. Equity Compensation Plan. The shares vest one year from the grant date."}],"balance_after":54193,"source":{"system":"sec-edgar","filing":"0001209191-20-036771","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919120036771/doc4.xml","form_type":"4"}},{"id":3398135,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-10-03T20:40:56.000Z","date":"2019-08-07","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest in full on August 7, 2020, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":25000,"derivative":{"exercise_price":2.93,"expiration_date":"2029-08-07","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001578563-19-000029","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000157856319000029/primary_doc.xml","form_type":"4"}},{"id":3437833,"issuer":{"id":128876,"kind":"organization","name":"BIODELIVERY SCIENCES INTERNATIONAL INC","symbol":"BDSI"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2019-08-15T16:25:27.000Z","date":"2019-08-13","kind":"exercise","acquired":false,"shares":21144,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (\"RSUs\") granted to the Reporting Person on August 1, 2018 under the Issuer's 2011 Equity Incentive Plan, as amended. The remaining RSUs under this grant will vest as follows: (i) 35,000 RSUs vest in the first open window following the Company's 2020 Annual Meeting of Stockholders, (ii) 35,000 RSUs vest in the first open window following the Company's 2021 Annual Meeting of Stockholders and (iii) 17,500 RSUs vest in the first open window following the Company's 2022 Annual Meeting of Stockholders."}],"balance_after":87500,"derivative":{"exercise_price":0,"expiration_date":"2022-08-01","underlying":"Common Stock","underlying_shares":21144},"source":{"system":"sec-edgar","filing":"0001103021-19-000006","document":"wf-form4_156590070881930.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1103021/000110302119000006/wf-form4_156590070881930.xml","form_type":"4"}},{"id":3437832,"issuer":{"id":128876,"kind":"organization","name":"BIODELIVERY SCIENCES INTERNATIONAL INC","symbol":"BDSI"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-08-15T16:25:27.000Z","date":"2019-08-13","kind":"exercise","acquired":true,"shares":21144,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (\"RSUs\") granted to the Reporting Person on August 1, 2018 under the Issuer's 2011 Equity Incentive Plan, as amended. The remaining RSUs under this grant will vest as follows: (i) 35,000 RSUs vest in the first open window following the Company's 2020 Annual Meeting of Stockholders, (ii) 35,000 RSUs vest in the first open window following the Company's 2021 Annual Meeting of Stockholders and (iii) 17,500 RSUs vest in the first open window following the Company's 2022 Annual Meeting of Stockholders."}],"balance_after":24788,"source":{"system":"sec-edgar","filing":"0001103021-19-000006","document":"wf-form4_156590070881930.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1103021/000110302119000006/wf-form4_156590070881930.xml","form_type":"4"}},{"id":3490395,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-06-14T17:49:02.000Z","date":"2019-06-13","kind":"grant","acquired":true,"shares":46729,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents grant of options to purchase shares of common stock, par value $0.01 per share, issued under the Antares Pharma, Inc. Equity Compensation Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vest and become exercisable one year from the grant date."}],"balance_after":46729,"derivative":{"exercise_price":2.92,"expiration_date":"2029-06-13","underlying":"Common Stock","underlying_shares":46729},"source":{"system":"sec-edgar","filing":"0001209191-19-037255","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919119037255/doc4.xml","form_type":"4"}},{"id":3490394,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-14T17:49:02.000Z","date":"2019-06-13","kind":"grant","acquired":true,"shares":23973,"price":2.92,"value":70001.16,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of restricted stock units made under the Antares Pharma, Inc. Equity Compensation Plan. The shares vest one year from the grant date. The reporting person has elected to defer the receipt of shares until separation of service as a Director."}],"balance_after":23973,"source":{"system":"sec-edgar","filing":"0001209191-19-037255","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919119037255/doc4.xml","form_type":"4"}},{"id":3508457,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-05-29T20:29:43.000Z","date":"2019-05-24","kind":"disposition_to_issuer","acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to an agreement between the Reporting Person and the Issuer, the Reporting Person agreed to forfeit the stock option for good and valuable consideration."}],"balance_after":0,"derivative":{"exercise_price":4.24,"expiration_date":"2028-03-27","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001578563-19-000017","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000157856319000017/primary_doc.xml","form_type":"4"}},{"id":3508456,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-05-29T20:29:43.000Z","date":"2019-05-24","kind":"disposition_to_issuer","acquired":true,"shares":364583,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents the forfeiture of 364,583 shares underlying the stock option.  Pursuant to an agreement between the Reporting Person and the Issuer, the Reporting Person agreed to forfeit the stock option for good and valuable consideration. The 135,417 shares underlying the stock option that have vested will not be forfeited."}],"balance_after":135417,"derivative":{"exercise_price":4.24,"expiration_date":"2028-03-27","underlying":"Common Stock","underlying_shares":364583},"source":{"system":"sec-edgar","filing":"0001578563-19-000017","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000157856319000017/primary_doc.xml","form_type":"4"}},{"id":3508455,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-05-29T20:29:43.000Z","date":"2019-05-24","kind":"disposition_to_issuer","acquired":true,"shares":325000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to an agreement between the Reporting Person and the Issuer, the Reporting Person agreed to forfeit the stock option for good and valuable consideration."}],"balance_after":0,"derivative":{"exercise_price":6.22,"expiration_date":"2029-04-01","underlying":"Common Stock","underlying_shares":325000},"source":{"system":"sec-edgar","filing":"0001578563-19-000017","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000157856319000017/primary_doc.xml","form_type":"4"}},{"id":3508454,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-29T20:29:43.000Z","date":"2019-05-24","kind":"disposition_to_issuer","acquired":false,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to an agreement between the Reporting Person and the Issuer, the Reporting Person agreed to forfeit the restricted stock units for good and valuable consideration."}],"balance_after":112500,"source":{"system":"sec-edgar","filing":"0001578563-19-000017","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000157856319000017/primary_doc.xml","form_type":"4"}},{"id":3567808,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-04-02T23:54:19.000Z","date":"2019-04-01","kind":"grant","acquired":true,"shares":325000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One fourth of the shares subject to the stock option will vest on the first anniversary of the date of grant, and the remaining three-fourths of the shares subject to the stock option will vest in equal monthly installments over the following 36 months."}],"balance_after":325000,"derivative":{"exercise_price":6.22,"expiration_date":"2029-04-01","underlying":"Common Stock","underlying_shares":325000},"source":{"system":"sec-edgar","filing":"0001578563-19-000014","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000157856319000014/primary_doc.xml","form_type":"4"}},{"id":3673741,"issuer":{"id":7940,"kind":"organization","name":"KIORA PHARMACEUTICALS INC","symbol":"KPRX"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-02-05T21:39:17.000Z","date":"2019-02-01","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to 100% of the shares underlying the Option on February 1, 2020."}],"balance_after":50000,"derivative":{"exercise_price":0.48,"expiration_date":"2029-02-01","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001144204-19-005050","document":"tv512448_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000114420419005050/tv512448_form4.xml","form_type":"4"}},{"id":3731214,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-12-14T18:49:45.000Z","date":"2018-12-13","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents initial grant of options, given to each director upon becoming a member of the board of directors, to purchase shares of common stock, par value of $0.01 per share, issued under the Antares Pharma, Inc. 2008 Equity Compensation Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest in equal quarterly installments over three years from the date of grant."}],"balance_after":20000,"derivative":{"exercise_price":3.11,"expiration_date":"2028-12-12","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-18-062812","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919118062812/doc4.xml","form_type":"4"}},{"id":3842162,"issuer":{"id":128876,"kind":"organization","name":"BIODELIVERY SCIENCES INTERNATIONAL INC","symbol":"BDSI"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2018-08-16T17:01:09.000Z","date":"2018-08-14","kind":"exercise","acquired":false,"shares":3644,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (\"RSUs\") granted to the Reporting Person on August 1, 2018 under the Issuer's 2011 Equity Incentive Plan, as amended. The remaining RSUs under this grant will vest as follows: (i) 21,144 RSUs vest in the first open window following the Company's 2019 Annual Meeting of Stockholders, (ii) 35,000 RSUs vest in the first open window following the Company's 2020 Annual Meeting of Stockholders, (iii) 35,000 RSUs vest in the first open window following the Company's 2021 Annual Meeting of Stockholders and (iv) 17,500 RSUs vest in the first open window following the Company's 2022 Annual Meeting of Stockholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (\"RSUs\") granted to the Reporting Person on August 1, 2018 under the Issuer's 2011 Equity Incentive Plan, as amended. The remaining RSUs under this grant will vest as follows: (i) 21,144 RSUs vest in the first open window following the Company's 2019 Annual Meeting of Stockholders, (ii) 35,000 RSUs vest in the first open window following the Company's 2020 Annual Meeting of Stockholders, (iii) 35,000 RSUs vest in the first open window following the Company's 2021 Annual Meeting of Stockholders and (iv) 17,500 RSUs vest in the first open window following the Company's 2022 Annual Meeting of Stockholders."}],"balance_after":108644,"derivative":{"exercise_price":0,"expiration_date":"2022-08-01","underlying":"Common Stock","underlying_shares":3644},"source":{"system":"sec-edgar","filing":"0000899243-18-022577","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1103021/000089924318022577/doc4.xml","form_type":"4"}},{"id":3842161,"issuer":{"id":128876,"kind":"organization","name":"BIODELIVERY SCIENCES INTERNATIONAL INC","symbol":"BDSI"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-08-16T17:01:09.000Z","date":"2018-08-14","kind":"exercise","acquired":true,"shares":3644,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (\"RSUs\") granted to the Reporting Person on August 1, 2018 under the Issuer's 2011 Equity Incentive Plan, as amended. The remaining RSUs under this grant will vest as follows: (i) 21,144 RSUs vest in the first open window following the Company's 2019 Annual Meeting of Stockholders, (ii) 35,000 RSUs vest in the first open window following the Company's 2020 Annual Meeting of Stockholders, (iii) 35,000 RSUs vest in the first open window following the Company's 2021 Annual Meeting of Stockholders and (iv) 17,500 RSUs vest in the first open window following the Company's 2022 Annual Meeting of Stockholders."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (\"RSUs\") granted to the Reporting Person on August 1, 2018 under the Issuer's 2011 Equity Incentive Plan, as amended. The remaining RSUs under this grant will vest as follows: (i) 21,144 RSUs vest in the first open window following the Company's 2019 Annual Meeting of Stockholders, (ii) 35,000 RSUs vest in the first open window following the Company's 2020 Annual Meeting of Stockholders, (iii) 35,000 RSUs vest in the first open window following the Company's 2021 Annual Meeting of Stockholders and (iv) 17,500 RSUs vest in the first open window following the Company's 2022 Annual Meeting of Stockholders."}],"balance_after":3644,"source":{"system":"sec-edgar","filing":"0000899243-18-022577","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1103021/000089924318022577/doc4.xml","form_type":"4"}},{"id":3849492,"issuer":{"id":7940,"kind":"organization","name":"KIORA PHARMACEUTICALS INC","symbol":"KPRX"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-08-08T20:15:55.000Z","date":"2018-07-27","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to 100% of the shares underlying the Option on July 27, 2019."}],"balance_after":50000,"derivative":{"exercise_price":0.57,"expiration_date":"2028-07-27","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001144204-18-042822","document":"tv500430_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000114420418042822/tv500430_4.xml","form_type":"4"}},{"id":3853614,"issuer":{"id":128876,"kind":"organization","name":"BIODELIVERY SCIENCES INTERNATIONAL INC","symbol":"BDSI"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-08-03T17:35:34.000Z","date":"2018-08-01","kind":"grant","acquired":true,"shares":64164,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options (\"options\") were issued to the Reporting Person on August 1, 2018, as compensation for service on the Issuer's board of directors. The options vest as follows: (i) 2,082 options vest in the first open window following the filing of the Company's quarterly 10Q for June 30, 2018, (ii) 12,082 options vest in the first open window following the Company's 2019 Annual Meeting of Stockholders, (iii) 20,000 options vest in the first open window following the Company's 2020 Annual Meeting of Stockholders, (iv) 20,000 options vest in the first open window following the Company's 2021 Annual Meeting of Stockholders and (v) 10,000 options vest in the first open window following the Company's 2022 Annual Meeting of Stockholders."}],"balance_after":64164,"derivative":{"exercise_price":2.93,"expiration_date":"2028-08-01","underlying":"Common Stock","underlying_shares":64164},"source":{"system":"sec-edgar","filing":"0000899243-18-021409","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1103021/000089924318021409/doc4.xml","form_type":"4"}},{"id":3853613,"issuer":{"id":128876,"kind":"organization","name":"BIODELIVERY SCIENCES INTERNATIONAL INC","symbol":"BDSI"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2018-08-03T17:35:34.000Z","date":"2018-08-01","kind":"grant","acquired":true,"shares":112288,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The restricted stock units (\"RSUs\") were issued to the Reporting Person on August 1, 2018, as compensation for service on the Issuer's board of directors. The RSUs vest as follows: (i) 3,644 RSUs vest in the first open window following the filing of the Company's quarterly 10Q for June 30, 2018, (ii) 21,144 RSUs vest in the first open window following the Company's 2019 Annual Meeting of Stockholders, (iii) 35,000 RSUs vest in the first open window following the Company's 2020 Annual Meeting of Stockholders, (iv) 35,000 RSUs vest in the first open window following the Company's 2021 Annual Meeting of Stockholders and (v) 17,500 RSUs vest in the first open window following the Company's 2022 Annual Meeting of Stockholders."}],"balance_after":112288,"derivative":{"exercise_price":0,"expiration_date":"2022-08-01","underlying":"Common Stock","underlying_shares":112288},"source":{"system":"sec-edgar","filing":"0000899243-18-021409","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1103021/000089924318021409/doc4.xml","form_type":"4"}},{"id":3923638,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2018-05-21T23:10:44.000Z","date":"2018-05-18","kind":"purchase","acquired":true,"shares":12500,"price":3.98,"value":49750.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades ranging from $3.95 to $4.00. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder full information regarding the number of shares and prices at which the transactions were effected."}],"balance_after":412500,"source":{"system":"sec-edgar","filing":"0001578563-18-000012","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000157856318000012/primary_doc.xml","form_type":"4"}},{"id":3979449,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-03-29T22:51:35.000Z","date":"2018-03-27","kind":"grant","acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option will vest in full upon the Issuer's common stock closing at or above $12.50 per share for three consecutive trading days, provided the Reporting Person is then an officer of the Issuer on each such vesting date."}],"balance_after":500000,"derivative":{"exercise_price":4.24,"expiration_date":"2028-03-27","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001104659-18-021354","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000110465918021354/a4.xml","form_type":"4"}},{"id":3979448,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-03-29T22:51:35.000Z","date":"2018-03-27","kind":"grant","acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option will vest 25% on the first anniversary of the date of grant and the remaining 75% of the shares subject to the stock option shall vest in equal monthly installments on each monthly anniversary date of the first vesting date over the following 48 months beginning on April 27, 2019, provided the Reporting Person is then an officer of the Issuer on each such vesting date."}],"balance_after":500000,"derivative":{"exercise_price":4.24,"expiration_date":"2028-03-27","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001104659-18-021354","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000110465918021354/a4.xml","form_type":"4"}},{"id":3979447,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2018-03-29T22:51:35.000Z","date":"2018-03-27","kind":"grant","acquired":true,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock which vests in four equal annual installments beginning on March 27, 2019, provided the Reporting Person is then an officer of the Issuer on each such vesting date.  The tax liability upon the vesting of the first annual installment shall be covered by the Issuer and the remaining tax liabilities upon the vesting of the second, third and fourth annual installments shall be covered by the Reporting Person."}],"balance_after":400000,"source":{"system":"sec-edgar","filing":"0001104659-18-021354","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000110465918021354/a4.xml","form_type":"4"}},{"id":4062298,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2018-02-13T21:54:02.000Z","date":"2018-02-13","kind":"disposition_to_issuer","acquired":false,"shares":237000,"price":6.15,"value":1457550.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the \"Option Spread\"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":11.85,"expiration_date":"2027-03-02","underlying":"Common Stock","underlying_shares":237000},"source":{"system":"sec-edgar","filing":"0001171843-18-001106","document":"formfour.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000117184318001106/formfour.xml","form_type":"4"}},{"id":4062297,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2018-02-13T21:54:02.000Z","date":"2018-02-13","kind":"disposition_to_issuer","acquired":false,"shares":420000,"price":4.2,"value":1764000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the \"Option Spread\"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":13.8,"expiration_date":"2026-03-02","underlying":"Common Stock","underlying_shares":420000},"source":{"system":"sec-edgar","filing":"0001171843-18-001106","document":"formfour.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000117184318001106/formfour.xml","form_type":"4"}},{"id":4062296,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2018-02-13T21:54:02.000Z","date":"2018-02-13","kind":"disposition_to_issuer","acquired":false,"shares":210000,"price":3.18,"value":667800.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the \"Option Spread\"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":14.82,"expiration_date":"2025-03-04","underlying":"Common Stock","underlying_shares":210000},"source":{"system":"sec-edgar","filing":"0001171843-18-001106","document":"formfour.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000117184318001106/formfour.xml","form_type":"4"}},{"id":4062295,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2018-02-13T21:54:02.000Z","date":"2018-02-13","kind":"disposition_to_issuer","acquired":false,"shares":200000,"price":12.1,"value":2420000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the \"Option Spread\"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":5.9,"expiration_date":"2024-07-31","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001171843-18-001106","document":"formfour.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000117184318001106/formfour.xml","form_type":"4"}},{"id":4062294,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2018-02-13T21:54:02.000Z","date":"2018-02-13","kind":"disposition_to_issuer","acquired":false,"shares":600000,"price":9.51,"value":5706000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the \"Option Spread\"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":8.49,"expiration_date":"2024-03-03","underlying":"Common Stock","underlying_shares":600000},"source":{"system":"sec-edgar","filing":"0001171843-18-001106","document":"formfour.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000117184318001106/formfour.xml","form_type":"4"}},{"id":4062293,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock, Class A","published_at":"2018-02-13T21:54:02.000Z","date":"2018-02-13","kind":"disposition_to_issuer","acquired":false,"shares":129729,"price":18,"value":2335122.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This common stock was purchased for $18.00 per share share in cash, subject to any required withholding of taxes and without interest, upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to that certain Agreement and Plan of Merger by and among Mallinckrodt plc, Sun Acquisition Co. and Sucampo Pharmaceuticals, Inc. dated December 23, 2017 (the \"Merger Agreement\"). The common stock consisted of both common stock and restricted stock units that were accelerated as a result of the Merger Agreement."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001171843-18-001106","document":"formfour.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000117184318001106/formfour.xml","form_type":"4"}},{"id":4106831,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock, Class A (ESPP)","published_at":"2018-01-04T22:16:44.000Z","date":"2017-12-31","kind":"grant","acquired":true,"shares":171,"price":9.1,"value":1556.1,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of common stock pursuant to the issuer's Employee Stock Purchase Plan (ESPP) for the period October 1, 2017 through December 31, 2017. This transaction is exempt under Rule 16(b)-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased at 85% of the July 3, 2017 closing price of the issuer's common stock."}],"balance_after":4792,"source":{"system":"sec-edgar","filing":"0001171843-18-000179","document":"formfour.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000117184318000179/formfour.xml","form_type":"4"}},{"id":4190817,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock, Class A (ESPP)","published_at":"2017-10-05T20:32:40.000Z","date":"2017-09-30","kind":"grant","acquired":true,"shares":659,"price":9.1,"value":5996.9,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of common stock pursuant to the issuer's Employee Stock Purchase Plan (ESPP) for the period July 1, 2017 through September 30, 2017. This transaction is exempt under Rule 16(b)-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased at 85% of the July 3, 2017 closing price of the issuer's common stock."}],"balance_after":4621,"source":{"system":"sec-edgar","filing":"0001171843-17-005956","document":"formfour.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000117184317005956/formfour.xml","form_type":"4"}},{"id":4248312,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-07-31T17:36:52.000Z","date":"2017-06-30","kind":"grant","acquired":true,"shares":8357,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options will vest in full on June 30, 2018, subject to the grantees continued service on such vesting date."}],"balance_after":8357,"derivative":{"exercise_price":0.57,"exercise_date":"2018-06-30","expiration_date":"2027-06-29","underlying":"Common Stock","underlying_shares":8357},"source":{"system":"sec-edgar","filing":"0001562180-17-002532","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000156218017002532/primarydocument.xml","form_type":"4"}},{"id":4260734,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock, Class A (ESPP)","published_at":"2017-07-07T20:45:19.000Z","date":"2017-06-30","kind":"grant","acquired":true,"shares":673,"price":8.93,"value":6009.89,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of common stock pursuant to the issuer's Employee Stock Purchase Plan (ESPP) for the period April 1, 2017 through June 30, 2017. This transaction is exempt under Rule 16(b)-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased at 85% of the June 30, 2017 closing price of the issuer's common stock."}],"balance_after":3962,"source":{"system":"sec-edgar","filing":"0001171843-17-004003","document":"formfour.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000117184317004003/formfour.xml","form_type":"4"}},{"id":4317857,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-05-16T23:04:05.000Z","date":"2017-05-12","kind":"grant","acquired":true,"shares":16714,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest in three substantially equal annual installments on May 11, 2018, 2019 and 2020, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":16714,"derivative":{"exercise_price":0.8,"expiration_date":"2027-05-11","underlying":"Common Stock","underlying_shares":16714},"source":{"system":"sec-edgar","filing":"0001209191-17-032881","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000120919117032881/doc4.xml","form_type":"4"}},{"id":4326384,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock, Class A (ESPP)","published_at":"2017-05-10T20:02:48.000Z","date":"2017-03-31","kind":"grant","acquired":true,"shares":641,"price":9.35,"value":5993.35,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of common stock pursuant to the issuer's Employee Stock Purchase Plan (ESPP) for the period January 1, 2017 through March 31, 2017. This transaction is exempt under Rule 16(b)-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased at 85% of the March 31, 2017 closing price of the issuer's common stock."}],"balance_after":3289,"source":{"system":"sec-edgar","filing":"0001171843-17-002919","document":"formfour.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000117184317002919/formfour.xml","form_type":"4"}},{"id":4394449,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-03-08T22:02:21.000Z","date":"2017-03-06","kind":"grant","acquired":true,"shares":237000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option will vest over a four-year period, with 25% vesting on March 2, 2018, and the remaining 75% vesting in equal monthly increments over the three-year period thereafter."}],"balance_after":1667000,"derivative":{"exercise_price":11.85,"expiration_date":"2027-03-02","underlying":"Class A Common Stock","underlying_shares":237000},"source":{"system":"sec-edgar","filing":"0001171843-17-001362","document":"f4_greenleaf030817.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000117184317001362/f4_greenleaf030817.xml","form_type":"4"}},{"id":4394448,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2017-03-08T22:02:21.000Z","date":"2017-03-06","kind":"grant","acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Common stock granted consists of restricted stock units that vest on March 2, 2020."}],"balance_after":125000,"source":{"system":"sec-edgar","filing":"0001171843-17-001362","document":"f4_greenleaf030817.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000117184317001362/f4_greenleaf030817.xml","form_type":"4"}},{"id":4484222,"issuer":{"id":4900,"kind":"organization","name":"Savara Inc","symbol":"SVRA"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2017-01-23T22:23:46.000Z","date":"2017-01-20","kind":"grant","acquired":true,"shares":45535,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units vest in full upon consummation of the merger transaction contemplated by the Agreement and Plan of Merger, dated January 6, 2017, by and among the issuer, Savara Inc., and Victoria Merger Corp. (provided such event occurs on or before July 6, 2017)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units vest in full upon consummation of the merger transaction contemplated by the Agreement and Plan of Merger, dated January 6, 2017, by and among the issuer, Savara Inc., and Victoria Merger Corp. (provided such event occurs on or before July 6, 2017)."}],"balance_after":45535,"derivative":{"underlying":"Common Stock","underlying_shares":45535},"source":{"system":"sec-edgar","filing":"0001209191-17-005145","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1160308/000120919117005145/doc4.xml","form_type":"4"}},{"id":4496040,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock, Class A (ESPP)","published_at":"2017-01-06T21:02:50.000Z","date":"2016-12-31","kind":"grant","acquired":true,"shares":135,"price":10.46,"value":1412.1,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of common stock pursuant to the issuer's Employee Stock Purchase Plan (ESPP) for the period October 1, 2016 through December 31, 2016. This transaction is exempt under Rule 16(b)-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased at 85% of the September 30, 2016 closing price of the issuer's common stock."}],"balance_after":2648,"source":{"system":"sec-edgar","filing":"0001171843-17-000124","document":"f4_010617greenleaf.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000117184317000124/f4_010617greenleaf.xml","form_type":"4"}},{"id":4538464,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2016-11-30T21:01:39.000Z","date":"2016-11-29","kind":"exercise","acquired":false,"shares":82459,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1430000,"derivative":{"exercise_price":6.75,"exercise_date":"2015-10-30","expiration_date":"2024-09-11","underlying":"Class A Common Stock","underlying_shares":82459},"source":{"system":"sec-edgar","filing":"0001171843-16-013441","document":"f4_greenleaf113016.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000117184316013441/f4_greenleaf113016.xml","form_type":"4"}},{"id":4538463,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2016-11-30T21:01:39.000Z","date":"2016-11-28","kind":"exercise","acquired":false,"shares":117541,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1512459,"derivative":{"exercise_price":6.75,"exercise_date":"2015-10-30","expiration_date":"2024-09-11","underlying":"Class A Common Stock","underlying_shares":117541},"source":{"system":"sec-edgar","filing":"0001171843-16-013441","document":"f4_greenleaf113016.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000117184316013441/f4_greenleaf113016.xml","form_type":"4"}},{"id":4538462,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock, Class A","published_at":"2016-11-30T21:01:39.000Z","date":"2016-11-29","kind":"sale","acquired":false,"shares":82459,"price":16.75,"value":1381188.25,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.75 to $16.78, inclusive. The reporting person will, upon request, provide any security holder of Sucampo Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission full information regarding the number of shares sold at each separate price within the range."}],"balance_after":2513,"source":{"system":"sec-edgar","filing":"0001171843-16-013441","document":"f4_greenleaf113016.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000117184316013441/f4_greenleaf113016.xml","form_type":"4"}},{"id":4538461,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock, Class A","published_at":"2016-11-30T21:01:39.000Z","date":"2016-11-29","kind":"exercise","acquired":true,"shares":82459,"price":6.75,"value":556598.25,"ownership":{"direct":true},"balance_after":84972,"source":{"system":"sec-edgar","filing":"0001171843-16-013441","document":"f4_greenleaf113016.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000117184316013441/f4_greenleaf113016.xml","form_type":"4"}},{"id":4538460,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock, Class A","published_at":"2016-11-30T21:01:39.000Z","date":"2016-11-28","kind":"sale","acquired":false,"shares":117541,"price":16.91,"value":1987618.31,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.80 to $17.35, inclusive. The reporting person will, upon request, provide any security holder of Sucampo Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission full information regarding the number of shares sold at each separate price within the range."}],"balance_after":2513,"source":{"system":"sec-edgar","filing":"0001171843-16-013441","document":"f4_greenleaf113016.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000117184316013441/f4_greenleaf113016.xml","form_type":"4"}},{"id":4538459,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock, Class A","published_at":"2016-11-30T21:01:39.000Z","date":"2016-11-28","kind":"exercise","acquired":true,"shares":117541,"price":6.75,"value":793401.75,"ownership":{"direct":true},"balance_after":120054,"source":{"system":"sec-edgar","filing":"0001171843-16-013441","document":"f4_greenleaf113016.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000117184316013441/f4_greenleaf113016.xml","form_type":"4"}},{"id":4576026,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock, Class A (ESPP)","published_at":"2016-10-21T20:06:03.000Z","date":"2016-09-30","kind":"grant","acquired":true,"shares":640,"price":9.38,"value":6003.2,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of common stock pursuant to the issuer's Employee Stock Purchase Plan (ESPP) for the period July 1, 2016 through September 30, 2016.  This transaction is exempt under Rule 16(b)-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased at 85% of the July 1, 2016 closing price of the issuer's common stock."}],"balance_after":2513,"source":{"system":"sec-edgar","filing":"0001171843-16-012575","document":"f4_greenleaf102116.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000117184316012575/f4_greenleaf102116.xml","form_type":"4"}},{"id":4611047,"issuer":{"id":7801,"kind":"organization","name":"SYNLOGIC, INC."},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2016-09-06T22:27:08.000Z","date":"2016-06-29","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and become exercisable in full on the earlier of (A) June 29, 2017 or (B) immediately prior to the next annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date."}],"balance_after":10000,"derivative":{"exercise_price":4.74,"expiration_date":"2026-06-29","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001140361-16-078995","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000114036116078995/doc1.xml","form_type":"4"}}]}